Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)

Victoria Chernyak; Kathryn J. Fowler; Jay P. Heiken; Claude B. Sirlin

doi:10.1002/jmri.26540

Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)

Victoria Chernyak, Kathryn J. Fowler, Jay P. Heiken, Claude B. Sirlin

Radiology

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Use of gadoxetate disodium, a hepatobiliary gadolinium-based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate-enhanced MRI may also serve as biomarkers of recurrence-free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI-RADS) imaging feature assessment and categorization. Level of Evidence: 5. Technical Efficacy Stage: 2. J. Magn. Reson. Imaging 2019;49:1236–1252.

Original language	English (US)
Pages (from-to)	1236-1252
Number of pages	17
Journal	Journal of Magnetic Resonance Imaging
Volume	49
Issue number	5
DOIs	https://doi.org/10.1002/jmri.26540
State	Published - May 2019

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1002/jmri.26540

Cite this

@article{0934577678054e4d8c5b204e916600b3,

title = "Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)",

abstract = "Use of gadoxetate disodium, a hepatobiliary gadolinium-based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate-enhanced MRI may also serve as biomarkers of recurrence-free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI-RADS) imaging feature assessment and categorization. Level of Evidence: 5. Technical Efficacy Stage: 2. J. Magn. Reson. Imaging 2019;49:1236–1252.",

author = "Victoria Chernyak and Fowler, {Kathryn J.} and Heiken, {Jay P.} and Sirlin, {Claude B.}",

note = "Publisher Copyright: {\textcopyright} 2019 International Society for Magnetic Resonance in Medicine",

year = "2019",

month = may,

doi = "10.1002/jmri.26540",

language = "English (US)",

volume = "49",

pages = "1236--1252",

journal = "Journal of Magnetic Resonance Imaging",

issn = "1053-1807",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)

AU - Chernyak, Victoria

AU - Fowler, Kathryn J.

AU - Heiken, Jay P.

AU - Sirlin, Claude B.

PY - 2019/5

Y1 - 2019/5

N2 - Use of gadoxetate disodium, a hepatobiliary gadolinium-based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate-enhanced MRI may also serve as biomarkers of recurrence-free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI-RADS) imaging feature assessment and categorization. Level of Evidence: 5. Technical Efficacy Stage: 2. J. Magn. Reson. Imaging 2019;49:1236–1252.

AB - Use of gadoxetate disodium, a hepatobiliary gadolinium-based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate-enhanced MRI may also serve as biomarkers of recurrence-free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI-RADS) imaging feature assessment and categorization. Level of Evidence: 5. Technical Efficacy Stage: 2. J. Magn. Reson. Imaging 2019;49:1236–1252.

UR - http://www.scopus.com/inward/record.url?scp=85059508801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059508801&partnerID=8YFLogxK

U2 - 10.1002/jmri.26540

DO - 10.1002/jmri.26540

M3 - Review article

C2 - 30609194

AN - SCOPUS:85059508801

SN - 1053-1807

VL - 49

SP - 1236

EP - 1252

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

IS - 5

ER -

Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this